研究氟喹诺酮类药物非那沙星对环丙沙星敏感和耐药鲍曼不动杆菌分离株的活性。
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.
机构信息
Institute for Medical Microbiology, Immunology, and Hygiene, University of Cologne, Goldenfelsstrasse 19-21, 50935 Cologne, Germany.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
Abstract
This study compared the activity of finafloxacin, a novel fluoroquinolone which shows enhanced activity under acidic pH, and that of ciprofloxacin against Acinetobacter baumannii under standard conditions (pH 7.2) and at a pH of 5.8. Overall, finafloxacin demonstrated superior activity to ciprofloxacin under acidic conditions. Furthermore, finafloxacin showed comparable activity to ciprofloxacin at pH 7.2. Hence, finafloxacin could be a promising new antimicrobial agent for the treatment of A. baumannii infections at acidic body compartments.
摘要
本研究比较了法氟沙星（一种新型氟喹诺酮类药物，在酸性 pH 值条件下具有增强的活性）和环丙沙星在标准条件（pH7.2）和 pH5.8 下对鲍曼不动杆菌的活性。总的来说，法氟沙星在酸性条件下比环丙沙星具有更强的活性。此外，法氟沙星在 pH7.2 时与环丙沙星具有相当的活性。因此，法氟沙星可能是治疗酸性体腔鲍曼不动杆菌感染的一种有前途的新型抗菌药物。
相似文献
1
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates.研究氟喹诺酮类药物非那沙星对环丙沙星敏感和耐药鲍曼不动杆菌分离株的活性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5. doi: 10.1128/AAC.01637-09. Epub 2010 Jan 25.
2
The Landscape of Phenotypic and Transcriptional Responses to Ciprofloxacin in Acinetobacter baumannii: Acquired Resistance Alleles Modulate Drug-Induced SOS Response and Prophage Replication.铜绿假单胞菌对环丙沙星表型和转录反应的研究：获得性耐药等位基因调节药物诱导的 SOS 反应和噬菌体复制。
mBio. 2019 Jun 11;10(3):e01127-19. doi: 10.1128/mBio.01127-19.
3
[Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].[临床鲍曼不动杆菌分离株氟喹诺酮耐药机制的研究]
Mikrobiyol Bul. 2016 Apr;50(2):278-86. doi: 10.5578/mb.24126.
4
Fluoroquinolone resistance conferred by gyrA, parC mutations, and AbaQ efflux pump among Acinetobacter baumannii clinical isolates causing ventilator-associated pneumonia.导致呼吸机相关性肺炎的鲍曼不动杆菌临床分离株中，gyrA、parC 基因突变和 AbaQ 外排泵赋予氟喹诺酮耐药性。
Acta Microbiol Immunol Hung. 2019 Dec 13;67(4):234-238. doi: 10.1556/030.66.2019.040.
5
Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii.在流行病学界定的鲍曼不动杆菌临床菌株中，gyrA和parC基因的突变与对氟喹诺酮类药物的耐药性相关。
J Antimicrob Chemother. 2003 Jan;51(1):177-80. doi: 10.1093/jac/dkf254.
6
Antimicrobial Resistance Mechanisms and Genetic Diversity of Multidrug-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Malaysia.从马来西亚一家教学医院分离出的多重耐药鲍曼不动杆菌的抗菌耐药机制及遗传多样性
Microb Drug Resist. 2017 Jul;23(5):545-555. doi: 10.1089/mdr.2016.0130. Epub 2016 Nov 17.
7
Development of highly ciprofloxacin-resistant laboratory mutants of Acinetobacter baumannii lacking topoisomerase IV gene mutations.缺乏拓扑异构酶IV基因突变的鲍曼不动杆菌高环丙沙星耐药实验室突变体的构建
J Antimicrob Chemother. 2006 Jan;57(1):155-6. doi: 10.1093/jac/dki397. Epub 2005 Nov 15.
8
Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.从美国加利福尼亚州洛杉矶县两次医院感染暴发中分离出的鲍曼不动杆菌菌株的分子特征及药敏性
BMC Infect Dis. 2016 May 4;16:194. doi: 10.1186/s12879-016-1526-y.
9
Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones.鲍曼不动杆菌对氟喹诺酮类药物耐药性的靶位突变和质粒相关耐药基因获得的影响。
Sci Rep. 2021 Oct 11;11(1):20136. doi: 10.1038/s41598-021-99230-y.
10
Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.鲍曼不动杆菌中与喹诺酮耐药相关的GyrA基因Ser83Leu和ParC基因Ser80Leu替换。
Microb Drug Resist. 2015 Jun;21(3):345-51. doi: 10.1089/mdr.2014.0057. Epub 2014 Dec 16.
引用本文的文献
1
An evaluation of antibiotic options for the treatment of biothreat pathogens.用于治疗生物威胁病原体的抗生素选择评估。
Front Antibiot. 2025 Aug 14;4:1611588. doi: 10.3389/frabi.2025.1611588. eCollection 2025.
2
Antibacterials with Novel Chemical Scaffolds in Clinical Development.处于临床开发阶段的具有新型化学骨架的抗菌药物。
Drugs. 2025 Mar;85(3):293-323. doi: 10.1007/s40265-024-02137-x. Epub 2025 Jan 23.
3
Location, Location, Location: Establishing Design Principles for New Antibacterials from Ferric Siderophore Transport Systems.位置，位置，位置：从铁载体转运系统中建立新型抗菌药物的设计原则。
Molecules. 2024 Aug 16;29(16):3889. doi: 10.3390/molecules29163889.
4
Layering vaccination with antibiotic therapy results in protection and clearance of in Balb/c mice.在Balb/c小鼠中，将疫苗接种与抗生素治疗分层可实现保护和清除。
Infect Immun. 2024 Mar 12;92(3):e0045523. doi: 10.1128/iai.00455-23. Epub 2024 Jan 30.
5
Activity of Finafloxacin against Panels of Respiratory Pathogens.非奈利酮对呼吸道病原体组的活性。
Antibiotics (Basel). 2023 Jun 23;12(7):1096. doi: 10.3390/antibiotics12071096.
6
adaptation to the host pH microenvironment is mediated by allelic variation in a single residue of BauA protein.对宿主pH微环境的适应性由BauA蛋白单个残基的等位基因变异介导。
PNAS Nexus. 2023 Mar 18;2(4):pgad079. doi: 10.1093/pnasnexus/pgad079. eCollection 2023 Apr.
7
Efficacy of finafloxacin in a murine model of inhalational glanders.非那沙星在吸入性鼻疽小鼠模型中的疗效
Front Microbiol. 2022 Nov 24;13:1057202. doi: 10.3389/fmicb.2022.1057202. eCollection 2022.
8
An Investigation into the Re-Emergence of Disease Following Cessation of Antibiotic Treatment in Balb/c Mice Infected with Inhalational .对感染吸入性病菌的Balb/c小鼠停止抗生素治疗后疾病再次出现的调查
Antibiotics (Basel). 2022 Oct 20;11(10):1442. doi: 10.3390/antibiotics11101442.
9
Investigation of a combination therapy approach for the treatment of melioidosis.治疗类鼻疽联合治疗方法的研究。
Front Microbiol. 2022 Aug 16;13:934312. doi: 10.3389/fmicb.2022.934312. eCollection 2022.
10
Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever.非那沙星，一种新型氟喹诺酮类药物，可减轻Q热小鼠模型中的感染临床症状和病理变化。
Front Microbiol. 2021 Nov 30;12:760698. doi: 10.3389/fmicb.2021.760698. eCollection 2021.
本文引用的文献
1
Fluoroquinolone resistance of Serratia marcescens: sucrose, salicylate, temperature, and pH induction of phenotypic resistance.粘质沙雷氏菌对氟喹诺酮的耐药性：蔗糖、水杨酸盐、温度和pH对表型耐药性的诱导
Can J Microbiol. 2007 Nov;53(11):1239-45. doi: 10.1139/W07-097.
2
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii.医院中日益严重的威胁：多重耐药鲍曼不动杆菌。
Nat Rev Microbiol. 2007 Dec;5(12):939-51. doi: 10.1038/nrmicro1789.
3
Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide.鲍曼不动杆菌中的多药外排抑制作用：1-(1-萘甲基)-哌嗪与苯丙氨酸-β-萘酰胺的比较
J Antimicrob Chemother. 2006 May;57(5):970-4. doi: 10.1093/jac/dkl081. Epub 2006 Mar 10.
4
Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide.pH对氟喹诺酮类、大环内酯类和酮内酯类药物体外活性及耐药性产生倾向的影响。
Infection. 2005 Dec;33 Suppl 2:36-43. doi: 10.1007/s15010-005-8206-y.
5
Regulation of Serratia marcescens ompF and ompC porin genes in response to osmotic stress, salicylate, temperature and pH.粘质沙雷氏菌外膜蛋白F和外膜蛋白C孔蛋白基因对渗透胁迫、水杨酸盐、温度及pH的响应调控
Microbiology (Reading). 2006 Feb;152(Pt 2):485-491. doi: 10.1099/mic.0.28428-0.
6
Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.鲍曼不动杆菌暴发期间拓扑异构酶突变的选择及adeB mRNA转录本的过表达
J Antimicrob Chemother. 2004 Oct;54(4):821-3. doi: 10.1093/jac/dkh427. Epub 2004 Sep 8.
7
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.1998年至2001年美国住院患者铜绿假单胞菌和鲍曼不动杆菌临床分离株的抗菌药物敏感性监测。
Antimicrob Agents Chemother. 2003 May;47(5):1681-8. doi: 10.1128/AAC.47.5.1681-1688.2003.
8
Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii.在流行病学界定的鲍曼不动杆菌临床菌株中，gyrA和parC基因的突变与对氟喹诺酮类药物的耐药性相关。
J Antimicrob Chemother. 2003 Jan;51(1):177-80. doi: 10.1093/jac/dkf254.
9
Physicochemical properties of quinolone antibiotics in various environments.喹诺酮类抗生素在不同环境中的物理化学性质。
Eur J Med Chem. 2002 Jun;37(6):443-60. doi: 10.1016/s0223-5234(02)01361-2.
10
Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro.吉米沙星对不动杆菌属的体外杀菌和抑菌活性
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:71-7. doi: 10.1093/jac/45.suppl_3.71.
Zotero 插件